CLINICAL-EPIDEMIOLOGICAL ANALYSIS OF HDL2 AND HDL3 SUBFRACTIONS IN ADULTS FROM MARACAIBO CITY, VENEZUELA
暂无分享,去创建一个
Ángel Ortega | M. Nava | J. Salazar | Valmore Bermúdez | Joselyn Rojas | M. Calvo | M. Chacín | M. Martínez | L. Olivar | Alex Morales-Carrasco | S. Linares
[1] M. Davidson. The Battle of the HDL Subfractions. , 2019, Cardiovascular revascularization medicine : including molecular interventions.
[2] Mohammad Hossein Khosravi,et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.
[3] I. Benseñor,et al. Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. , 2018, Journal of clinical lipidology.
[4] A. M. Figueiredo Neto,et al. Insulin Resistance Predicts Atherogenic Lipoprotein Profile in Nondiabetic Subjects , 2017, Journal of diabetes research.
[5] Joselyn Rojas,et al. HDL-C y riesgo de aterosclerosis , 2016 .
[6] Kengo Moriyama,et al. HDL2/HDL3 Ratio Changes, Metabolic Syndrome Markers, and Other Factors in a Japanese Population. , 2016, Journal of atherosclerosis and thrombosis.
[7] Mervin Chávez-Castillo,et al. Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics , 2015, Cholesterol.
[8] E. Kabré,et al. Reference Ranges of Cholesterol Sub-Fractions in Random Healthy Adults in Ouagadougou, Burkina Faso , 2015, PloS one.
[9] J. López-Miranda,et al. Epidemiologic Behavior and Estimation of an Optimal Cut-Off Point for Homeostasis Model Assessment-2 Insulin Resistance: A Report from a Venezuelan Population , 2014, International scholarly research notices.
[10] S. Martin,et al. High-density lipoprotein subfractions: current views and clinical practice applications , 2014, Trends in Endocrinology & Metabolism.
[11] T. Hatsukami,et al. HDL‐3 is a Superior Predictor of Carotid Artery Disease in a Case‐Control Cohort of 1725 Participants , 2014, Journal of the American Heart Association.
[12] J. Salazar,et al. Variations of Lipoprotein(a) Levels in the Metabolic Syndrome: A Report from the Maracaibo City Metabolic Syndrome Prevalence Study , 2013, Journal of diabetes research.
[13] G. Norata,et al. High-Density Lipoprotein Subfractions - What the Clinicians Need to Know , 2013, Cardiology.
[14] T. Lüscher,et al. Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease , 2012, EMBO molecular medicine.
[15] Paul T. Williams. Fifty-three year follow-up of coronary heart disease versus HDL2 and other lipoproteins in Gofman's Livermore Cohort[S] , 2012, Journal of Lipid Research.
[16] M. Velasco,et al. The Maracaibo city metabolic syndrome prevalence study: design and scope. , 2010, American journal of therapeutics.
[17] J. Cleeman,et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Forceon Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World HeartFederation; International Atherosclerosis Society; and International Asso , 2010 .
[18] S. Grundy,et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.
[19] H. Tian,et al. Alterations of high-density lipoprotein subclasses in hypercholesterolemia and combined hyperlipidemia. , 2007, International journal of cardiology.
[20] J. Fragoso,et al. Small HDL subclasses become cholesterol-poor during postprandial period after a fat diet intake in subjects with high triglyceridemia increases. , 2017, Clinica chimica acta; international journal of clinical chemistry.
[21] P. Joshi,et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. , 2015, European heart journal.
[22] Milagros Rojas,et al. The Maracaibo city metabolic syndrome prevalence study: primary results and agreement level of 3 diagnostic criteria , 2014 .
[23] M. Velasco,et al. High-sensitivity c-reactive protein epidemiological behavior in adult individuals from Maracaibo , Venezuela , 2013 .
[24] Who Consultation on Obesity. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. , 2000, World Health Organization technical report series.
[25] J. Gofman,et al. Ultracentrifugal analysis of serum lipoproteins. , 1954, Methods of biochemical analysis.